<DOC>
	<DOCNO>NCT02980458</DOCNO>
	<brief_summary>The present study conduct order compare bioavailability generic Test product ( Deferiprone 500 Lipomed tablet , Lipomed AG , Switzerland ) market Reference product ( Ferriprox® film-coated tablet , Apotex Europe B.V. , Germany ) contain 500 mg deferiprone . For issue pharmacokinetics characterise single dose administration one tablet .</brief_summary>
	<brief_title>Characterisation Relative Bioavailability With Bioequivalence Assessment Deferiprone Tablets After Oral Single Dose Administration</brief_title>
	<detailed_description>The study perform open-label , randomise ( order treatment ) , single dose , 2 period cross-over design wash phase least three treatment free day administration . Sample collection perform eight hour fast administration . This time consider adequate determination plasma concentration vs. time profile long enough reliable estimation extent absorption , i.e . AUC derive measurement expect cover least 80 % AUC extrapolate infinity deferiprone</detailed_description>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>1. sex : male 2. ethnic origin : Caucasian 3. age : 18 year old 4. bodymass index ( BMI ) : &gt; =18.5 kg/m² &lt; = 30.0 kg/m² 5. good state health 6. nonsmoker exsmoker least 1 month 7. write informed consent , inform benefit potential risk clinical trial , well detail insurance take cover subject participate clinical trial 1. exist cardiac and/or haematological disease pathological finding , might interfere safety tolerability active ingredient 2. exist hepatic and/or renal disease pathological finding , might interfere safety tolerability , and/or pharmacokinetics active ingredient 3. exist gastrointestinal disease pathological finding , might interfere safety , tolerability , absorption and/or pharmacokinetics active ingredient 4. history relevant CNS and/or psychiatric disorder and/or currently treat CNS and/or psychiatric disorder 5. know allergic reaction active ingredient use constituent pharmaceutical preparation 6. subject severe allergy multiple drug allergy unless judge relevant clinical trial investigator 7. heart rate &lt; 50 bpm 8. laboratory value normal range unless deviation normal judge relevant clinical trial investigator 9. laboratory value : CRP &gt; 5 mg/L , ASAT &gt; 20 % ULN , ALAT &gt; 10 % ULN , bilirubin &gt; 20 % ULN creatinine &gt; 0.1 mg/dL 10. positive antiHIVtest ( positive verify western blot ) , HBsAGtest ( positive verify test HBcIgM ) antiHCVtest 11. history recurrent episodes neutropenia history agranulocytosis 12. acute chronic disease may interfere pharmacokinetics IMP 13. history current drug alcohol dependence 14. regular intake alcoholic food beverage ≥ 40 g pure ethanol male per day 15. subject diet could affect pharmacokinetics active ingredient 16. regular intake caffeine contain food beverage ≥ 500 mg caffeine per day 17. blood donation blood loss 400 ml within last 2 month prior individual enrolment subject 18. administration investigational medicinal product last 2 month prior individual enrolment subject 19. regular treatment systemically available medication 20. treatment medicinal product might cause neutropenia agranulocytosis 21. subject , report frequent occurrence migraine attack 22. subject suspect know follow instruction 23. subject unable understand write verbal instruction , particular regard risk inconvenience expose participation clinical trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Deferiprone</keyword>
</DOC>